Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 1516 to 1530 of 7959 results

  1. Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA602)

    NICE is unable to make a recommendation on pomalidomide (Imnovid) with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma in adults. This is because Celgene did not provide an evidence submission.

    Sections for TA602

  2. Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA603)

    NICE is unable to make a recommendation on lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma in adults. This is because Celgene did not provide an evidence submission.

    Sections for TA603

  3. Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal) (TA1058)

    NICE is unable to make a recommendation on tislelizumab (Tevimbra) in combination for untreated advanced non-small-cell lung cancer in adults. This is because the company did not provide an evidence submission.

    Sections for TA1058

  4. Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over (HST33)

    Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.

  5. Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) (TA608)

    NICE is unable to make a recommendation on ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults. This is because Janssen did not provide an evidence submission.

    Sections for TA608

  6. Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)

    NICE is unable to make a recommendation on ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma in adults who have had sorafenib. This is because Lilly did not provide an evidence submission.

    Sections for TA609

  7. Idelalisib for treating refractory follicular lymphoma (TA604)

    Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.

  8. Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.

  9. Guidance on the use of coronary artery stents (TA71)

    Evidence-based recommendations on using coronary artery stents in adults.

  10. Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction (TA73)

    Evidence-based recommendations on myocardial perfusion scintigraphy for diagnosing and managing angina and myocardial infarction in adults.

  11. HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) (TA92)

    Evidence-based recommendations on using an ozone-releasing device (HealOzone) in people with tooth decay.

  12. Tacrolimus and pimecrolimus for atopic eczema (TA82)

    Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.

  13. Laparoscopic surgery for inguinal hernia repair (TA83)

    Evidence-based recommendations on laparoscopic surgery for treating inguinal hernia.

  14. Frequency of application of topical corticosteroids for atopic eczema (TA81)

    Evidence-based recommendations on using topical corticosteroids for people with atopic eczema.

  15. Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)

    Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.